Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

ABSTRACT: Determining when to start antiretroviral treatment (ART) is vitally important for people living with HIV. Yet the optimal point at which to start to maximize clinical benefit remains unknown. In the absence of randomized studies, current guidelines rely on conflicting observational data and expert opinion, and consequently diverge on this point. In the USA, ART is recommended irrespective of CD4 cell count. The World Health Organization now recommends starting ART at a CD4 cell count of 500 cells/μL, while the threshold for the UK and South Africa remains at 350 cells/μL. The Strategic Timing of AntiRetroviral Treatment (START) study, one of the largest clinical trials on the treatment of HIV infection, will answer this question. START compares two treatment strategies: immediate treatment

SUBMITTER: Geffen N 

PROVIDER: S-EPMC4341942 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature